Emel Saglar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Emel Saglar has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Beril Erdem
Department of Biology, Faculty of Science, Hacettepe University, Ankara, Turkey
12 shared publications - Hatice Mergen
Department of Biology, Faculty of Science, Hacettepe University, Ankara, Turkey
10 shared publications Merve Ozcan
5 shared publicationsTugce Karaduman
5 shared publicationsFerhat Deniz
4 shared publicationsArif Yonem
2 shared publications
Latest Publications
- 19 May 2026
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 26, 1-9
The Biological Effects of Biochanin A on Glioblastoma T98G Cells and Evaluation of Endoplasmic Reticulum Stress Genes
Introduction: Glioblastoma multiforme is one of the common central nervous system tumors characterized by a low survival rate and a high risk of recurrence. This study aimed to investigate the cell viability and ER stress in the T98G glioma cell line after the application of Biochanin A, an isoflavone. Methods: A non-toxic dose was determined for T98G cells after Biochanin A application. Then, using a non-toxic concentration of Biochanin A, a flow cytometry experiment was performed for apoptotic cell ratios, quantitative Real-time PCR was performed to verify the expression levels of GRP78, ATF4, EIF2S1, and XBP1 genes that are associated with ER stress, a wound healing assay was performed to show cellular migration, and intracellular Ca2+ levels were determined. Results: The ratio of early and late apoptosis was low for the control group compared to Biochanin A-treated cells. Although it was not statistically significant, a trend towards increased apoptosis was observed after Biochanin A application. Biochanin A-treated T98G cells showed reduced migration compared to control cells. Among the studied genes, ATF4 was statistically upregulated (p=0.0002) while no changes in intracellular Ca2+ level were observed. Discussion: In this study, the effects of Biochanin A application on glioblastoma cells were evaluated from the perspective of cell viability and ER stress. We concluded that Biochanin A application upregulates the ATF4 gene expression, which has important roles during tumor progression and affects the migration of T98G glioblastoma cells. Conclusion: The results of the study will contribute to the development of new treatment strategies supported by isoflavones such as Biochanin A.
- 19 May 2026
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 26, 1-9
The Biological Effects of Biochanin A on Glioblastoma T98G Cells and Evaluation of Endoplasmic Reticulum Stress Genes
Introduction: Glioblastoma multiforme is one of the common central nervous system tumors characterized by a low survival rate and a high risk of recurrence. This study aimed to investigate the cell viability and ER stress in the T98G glioma cell line after the application of Biochanin A, an isoflavone. Methods: A non-toxic dose was determined for T98G cells after Biochanin A application. Then, using a non-toxic concentration of Biochanin A, a flow cytometry experiment was performed for apoptotic cell ratios, quantitative Real-time PCR was performed to verify the expression levels of GRP78, ATF4, EIF2S1, and XBP1 genes that are associated with ER stress, a wound healing assay was performed to show cellular migration, and intracellular Ca2+ levels were determined. Results: The ratio of early and late apoptosis was low for the control group compared to Biochanin A-treated cells. Although it was not statistically significant, a trend towards increased apoptosis was observed after Biochanin A application. Biochanin A-treated T98G cells showed reduced migration compared to control cells. Among the studied genes, ATF4 was statistically upregulated (p=0.0002) while no changes in intracellular Ca2+ level were observed. Discussion: In this study, the effects of Biochanin A application on glioblastoma cells were evaluated from the perspective of cell viability and ER stress. We concluded that Biochanin A application upregulates the ATF4 gene expression, which has important roles during tumor progression and affects the migration of T98G glioblastoma cells. Conclusion: The results of the study will contribute to the development of new treatment strategies supported by isoflavones such as Biochanin A.
- Open Access
- 1 January 2026
- Published by Discovery Medicine in Discovery Medicine
- Vol. 38 (206) , 660-669
Pharmacological Chaperoning by Vaptans: Restoring Function of NDI-Causing AVPR2 Mutants In Vitro
Nephrogenic diabetes insipidus (NDI) is a rare disease characterized by the inability of the kidney to respond to vasopressin and concentrate urine. Hereditary NDI is primarily caused by mutations in the arginine vasopressin receptor-2 (AVPR2) gene, which enables the response to antidiuretic hormone. Mutations may lead to misfolding of the mutant AVPR2 protein or its retention within the Endoplasmic reticulum of the cell. Therefore, patients cannot respond to antidiuretic hormone and concentrate urine. Consequently, in untreated patients severe dehydration and hypernatremia may occur depending on the severity of the disease. Low-sodium and protein diet, using thiazide diuretics, and amiloride treatment are the conventional and standard treatments for NDI. Besides, many in vitro functional analysis studies have been focused on pharmacological chaperones for restoring function of NDI-causing AVPR2 mutants. Vaptans, which are known as vasopressin receptor antagonists and also pharmacological chaperones, are among the current and controversial topics for developing new treatment strategies for NDI. This study aims to review the in vitro studies on vaptans which are targeted to restore expression and function of mutant AVPR2s that cause NDI and highlight the importance of their effectiveness according to the type of mutation.
- 1 January 2026
- Published by Discovery Medicine in Discovery Medicine
- Vol. 38 (206) , 660-669
Open AccessPharmacological Chaperoning by Vaptans: Restoring Function of NDI-Causing AVPR2 Mutants In Vitro
Nephrogenic diabetes insipidus (NDI) is a rare disease characterized by the inability of the kidney to respond to vasopressin and concentrate urine. Hereditary NDI is primarily caused by mutations in the arginine vasopressin receptor-2 (AVPR2) gene, which enables the response to antidiuretic hormone. Mutations may lead to misfolding of the mutant AVPR2 protein or its retention within the Endoplasmic reticulum of the cell. Therefore, patients cannot respond to antidiuretic hormone and concentrate urine. Consequently, in untreated patients severe dehydration and hypernatremia may occur depending on the severity of the disease. Low-sodium and protein diet, using thiazide diuretics, and amiloride treatment are the conventional and standard treatments for NDI. Besides, many in vitro functional analysis studies have been focused on pharmacological chaperones for restoring function of NDI-causing AVPR2 mutants. Vaptans, which are known as vasopressin receptor antagonists and also pharmacological chaperones, are among the current and controversial topics for developing new treatment strategies for NDI. This study aims to review the in vitro studies on vaptans which are targeted to restore expression and function of mutant AVPR2s that cause NDI and highlight the importance of their effectiveness according to the type of mutation.
- Open Access
- 25 October 2024
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (6) , 1577-1586
Investigation of Fibrillar Aggregates Formed by Pathogenic Pre-pro-vasopressin Mutants that Cause ADNDI
Context Aggregations of unfolded or misfolded proteins, both inside and outside cells, are implicated in numerous diseases, collectively known as amyloidosis. Particularly, Autosomal dominant neurohypophyseal diabetes insipidus (ADNDI) is a rare disease caused by mutations in the AVP-NPII gene, leading to the inability to secrete arginine vasopressin (AVP). These misfolded proteins accumulate within the endoplasmic reticulum (ER), causing cellular dysfunction. Objective This study aimed to investigate the formation of amyloid-like aggregates within the cell resulting from misfolded mutant precursor proteins, which induce disulfide-linked oligomers due to the G45C, 207_209delGGC, G88V, C98X, C104F, E108D-1, E108D-2 and R122H mutations identified by our group in the AVP-NPII gene of ADNDI patients. Methods De-glycosylation studies were performed to analyze the glycosylation patterns of mutant protein precursors. The involvement of these precursors in the ER-related degradation pathway was studied by conducting protease inhibition experiments. Disulfide-linked oligomer analysis determined the oligomerization status of the mutant precursors. Immunofluorescence and electron microscopy studies provided evidence of aggregate structures in the ER lumen. In vitro studies involving bacterial expression and fibril formation in E. coli. Results Our findings demonstrated that the N-glycan structure of mutant precursors remains intact within the ER. Protease inhibition experiments indicated the involvement of these precursors in the ER-related degradation pathway. Disulfide-linked oligomer analysis revealed homo-oligomer structures in mutations. Immunofluorescence and electron microscopy studies confirmed the presence of aggregate structures in the ER lumen. In vitro studies showed that mutant precursors could form fibril structures in E. coli. Conclusion Our study may support the idea that ADNDI belongs to the group of neurodegenerative diseases due to the formation of fibrillar amyloid aggregates in the cell.
- 25 October 2024
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (6) , 1577-1586
Open AccessInvestigation of Fibrillar Aggregates Formed by Pathogenic Pre-pro-vasopressin Mutants that Cause ADNDI
Context Aggregations of unfolded or misfolded proteins, both inside and outside cells, are implicated in numerous diseases, collectively known as amyloidosis. Particularly, Autosomal dominant neurohypophyseal diabetes insipidus (ADNDI) is a rare disease caused by mutations in the AVP-NPII gene, leading to the inability to secrete arginine vasopressin (AVP). These misfolded proteins accumulate within the endoplasmic reticulum (ER), causing cellular dysfunction. Objective This study aimed to investigate the formation of amyloid-like aggregates within the cell resulting from misfolded mutant precursor proteins, which induce disulfide-linked oligomers due to the G45C, 207_209delGGC, G88V, C98X, C104F, E108D-1, E108D-2 and R122H mutations identified by our group in the AVP-NPII gene of ADNDI patients. Methods De-glycosylation studies were performed to analyze the glycosylation patterns of mutant protein precursors. The involvement of these precursors in the ER-related degradation pathway was studied by conducting protease inhibition experiments. Disulfide-linked oligomer analysis determined the oligomerization status of the mutant precursors. Immunofluorescence and electron microscopy studies provided evidence of aggregate structures in the ER lumen. In vitro studies involving bacterial expression and fibril formation in E. coli. Results Our findings demonstrated that the N-glycan structure of mutant precursors remains intact within the ER. Protease inhibition experiments indicated the involvement of these precursors in the ER-related degradation pathway. Disulfide-linked oligomer analysis revealed homo-oligomer structures in mutations. Immunofluorescence and electron microscopy studies confirmed the presence of aggregate structures in the ER lumen. In vitro studies showed that mutant precursors could form fibril structures in E. coli. Conclusion Our study may support the idea that ADNDI belongs to the group of neurodegenerative diseases due to the formation of fibrillar amyloid aggregates in the cell.
- Open Access
- 20 August 2024
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 49 (5) , 685-690
Effects of YM087 and VPA985 on the T237M mutant receptor functionality in nephrogenic diabetes insipidus
Objectives: Mutations detected in the AVPR2 gene (arginine vasopressin type 2 receptor) are known to cause nephrogenic diabetes insipidus (NDI). Several pharmacological chaperones (PCs) target misfolded AVPR2 proteins and rescue them from the quality control system of the cell. In this study, we investigated the effect of YM087 and VPA985, which are PCs, on T273M-AVPR2 mutant that are known to cause NDI. Methods: The total and cell surface expressions of T273M in COS-1 cells were measured by sandwich ELISA and flow cytometry after the cells were treated with YM087 and VPA985 separately. In addition, the cAMP accumulation assay was performed. Results: It was observed that VPA985 treatment significantly increased the cell surface expression and slightly increased the maximum cAMP response of T273M. Both YM087 and VPA985 decreased the ligand concentrations which were responsible for making half of the maximum response of the T273M mutant receptor. Conclusions: PCs have different potential effects on different AVPR2 mutants. Therefore, studying the effectiveness of PCs in rescuing AVPR2 mutants and making them functional again may contribute to the development of new therapeutic strategies.
- 20 August 2024
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 49 (5) , 685-690
Open AccessEffects of YM087 and VPA985 on the T237M mutant receptor functionality in nephrogenic diabetes insipidus
Objectives: Mutations detected in the AVPR2 gene (arginine vasopressin type 2 receptor) are known to cause nephrogenic diabetes insipidus (NDI). Several pharmacological chaperones (PCs) target misfolded AVPR2 proteins and rescue them from the quality control system of the cell. In this study, we investigated the effect of YM087 and VPA985, which are PCs, on T273M-AVPR2 mutant that are known to cause NDI. Methods: The total and cell surface expressions of T273M in COS-1 cells were measured by sandwich ELISA and flow cytometry after the cells were treated with YM087 and VPA985 separately. In addition, the cAMP accumulation assay was performed. Results: It was observed that VPA985 treatment significantly increased the cell surface expression and slightly increased the maximum cAMP response of T273M. Both YM087 and VPA985 decreased the ligand concentrations which were responsible for making half of the maximum response of the T273M mutant receptor. Conclusions: PCs have different potential effects on different AVPR2 mutants. Therefore, studying the effectiveness of PCs in rescuing AVPR2 mutants and making them functional again may contribute to the development of new therapeutic strategies.
- 5 January 2022
- Published by Hacettepe University in Hacettepe Journal of Biology and Chemistry
- Vol. 50 (1) , 37-43
CHEMICAL CHAPERONE EFFECTS ON ARGININE-VASOPRESSIN RECEPTOR 2 MUTANTS
Improper folding of the mutant proteins may finally cause several conformational diseases such as Nephrogenic Diabetes Insipidus (NDI). In recent years, as a therapeutic strategy, chaperone treatment for such diseases is among current issues. In our study, we aimed to analyze the effect of several chemical chaperones on mutant V2 receptors which cause NDI. V2R mutant constructs were introduced into the pLV2R. Mutants were transiently expressed in COS-7 cells. After MTT analyses, cell surface ELISA experiment was performed for understanding the rescue potential of the chaperones of the mutated proteins. As a result, we analyzed that rescue potential of a chemical chaperone depends on both chemical compound and the mutation type. We may conclude that such chaperone treatment studies are valuable for development of the therapeutic strategies.
- 5 January 2022
- Published by Hacettepe University in Hacettepe Journal of Biology and Chemistry
- Vol. 50 (1) , 37-43
CHEMICAL CHAPERONE EFFECTS ON ARGININE-VASOPRESSIN RECEPTOR 2 MUTANTS
Improper folding of the mutant proteins may finally cause several conformational diseases such as Nephrogenic Diabetes Insipidus (NDI). In recent years, as a therapeutic strategy, chaperone treatment for such diseases is among current issues. In our study, we aimed to analyze the effect of several chemical chaperones on mutant V2 receptors which cause NDI. V2R mutant constructs were introduced into the pLV2R. Mutants were transiently expressed in COS-7 cells. After MTT analyses, cell surface ELISA experiment was performed for understanding the rescue potential of the chaperones of the mutated proteins. As a result, we analyzed that rescue potential of a chemical chaperone depends on both chemical compound and the mutation type. We may conclude that such chaperone treatment studies are valuable for development of the therapeutic strategies.
- 2 July 2021
- Published by Springer Nature in Biologia
- Vol. 76 (9) , 2767-2776
Functional analysis of AQP2 mutants found in patients with diabetes insipidus
- 2 July 2021
- Published by Springer Nature in Biologia
- Vol. 76 (9) , 2767-2776
Functional analysis of AQP2 mutants found in patients with diabetes insipidus
- 1 December 2019
- Published by Elsevier in European Journal of Pharmacology
- Vol. 865, 172803
Evaluation of pharmacochaperone-mediated rescue of mutant V2 receptor proteins
- 1 December 2019
- Published by Elsevier in European Journal of Pharmacology
- Vol. 865, 172803
Evaluation of pharmacochaperone-mediated rescue of mutant V2 receptor proteins
- 13 July 2019
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 77 (5) , 953-962
Molecular characterization of an aquaporin-2 mutation causing a severe form of nephrogenic diabetes insipidus
The water channel aquaporin 2 (AQP2) is responsible for water reabsorption by kidney collecting duct cells. A substitution of amino acid leucine 137 to proline in AQP2 (AQP2-L137P) causes Nephrogenic Diabetes Insipidus (NDI). This study aimed to determine the cell biological consequences of this mutation on AQP2 function. Studies were performed in HEK293 and MDCK type I cells, transfected with wildtype (WT) AQP2 or an AQP2-L137P mutant. AQP2-L137P was predominantly detected as a high-mannose form of AQP2, whereas AQP2-WT was observed in both non-glycosylated and complex glycosylated forms. In contrast to AQP2-WT, the AQP2-L137P mutant did not accumulate on the apical plasma membrane following stimulation with forskolin. Ubiquitylation of AQP2-L137P was different from AQP2-WT, with predominance of non-distinct protein bands at various molecular weights. The AQP2-L137P mutant displayed reduced half-life compared to AQP2-WT. Treatment of cells with chloroquine increased abundance of AQP2-WT, but not AQP2-L137P. In contrast, treatment with MG132 increased abundance of AQP2-L137P but not AQP2-WT. Xenopus oocytes injected with AQP2-WT had increased osmotic water permeability when compared to AQP2-L137P, which correlated with lack of the mutant form in the plasma membrane. From the localization of the mutation and nature of the substitution it is likely that AQP2-L137P causes protein misfolding, which may be responsible for the observed functional defects. The data suggest that the L137P mutation results in altered AQP2 protein maturation, increased AQP2 degradation via the proteasomal pathway and limited plasma membrane expression. These combined mechanisms are likely responsible for the phenotype observed in this class of NDI patients.
- 13 July 2019
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 77 (5) , 953-962
Molecular characterization of an aquaporin-2 mutation causing a severe form of nephrogenic diabetes insipidus
The water channel aquaporin 2 (AQP2) is responsible for water reabsorption by kidney collecting duct cells. A substitution of amino acid leucine 137 to proline in AQP2 (AQP2-L137P) causes Nephrogenic Diabetes Insipidus (NDI). This study aimed to determine the cell biological consequences of this mutation on AQP2 function. Studies were performed in HEK293 and MDCK type I cells, transfected with wildtype (WT) AQP2 or an AQP2-L137P mutant. AQP2-L137P was predominantly detected as a high-mannose form of AQP2, whereas AQP2-WT was observed in both non-glycosylated and complex glycosylated forms. In contrast to AQP2-WT, the AQP2-L137P mutant did not accumulate on the apical plasma membrane following stimulation with forskolin. Ubiquitylation of AQP2-L137P was different from AQP2-WT, with predominance of non-distinct protein bands at various molecular weights. The AQP2-L137P mutant displayed reduced half-life compared to AQP2-WT. Treatment of cells with chloroquine increased abundance of AQP2-WT, but not AQP2-L137P. In contrast, treatment with MG132 increased abundance of AQP2-L137P but not AQP2-WT. Xenopus oocytes injected with AQP2-WT had increased osmotic water permeability when compared to AQP2-L137P, which correlated with lack of the mutant form in the plasma membrane. From the localization of the mutation and nature of the substitution it is likely that AQP2-L137P causes protein misfolding, which may be responsible for the observed functional defects. The data suggest that the L137P mutation results in altered AQP2 protein maturation, increased AQP2 degradation via the proteasomal pathway and limited plasma membrane expression. These combined mechanisms are likely responsible for the phenotype observed in this class of NDI patients.
- 8 May 2018
- Published by Bioscientifica in Endocrine Abstracts
Tolvaptan; OPC-41 061, Mozavaptan; OPC-31 260, OPC-21 268 as pharmacological chaperones to rescue of mutant AVPR2s
Nefrojenic Diabetes insipidus is one of the typical conformational disorders result from protein misfolding and degredation or aggregation due to the mutations in AVPR2. The patients of nephrogenic Diabetes insipidus have difficulty in concentrate of urine and because of this, they have polyuria, hypoosmolar urine and hypernatremia in variable levels. To make them relieved, many treatment strategies have been studying and using dDAVP nasally is one of these strategies. Another treatment approach on this type of conformational disease is in vitro treatment of mutant AVPR2s with pharmacological chaperones (PCs). PCs are small molecules that bind to misfolded proteins and stabilize them and rescue these mutated proteins from quality control system of Endoplasmic reticulum. In this study, Tolvaptan; OPC-41 061, Mozavaptan; OPC-31 260 and OPC-21 268 were selected as pharmacological chaperones for treatment of previously identified and functionally analyzed mutations (R68W, DR67_G69/G107W and T273M) by our group. As a functional analysis, we performed cell surface ELISA after the treatment of mutant AVPR2s with OPC-41 061, OPC-31 260 and OPC-21 268. Our study was supported by The Scientific and Technological Research Council of Turkey (SBAG Project number 216S304). According to the ELISA results, some mutant AVPR2s could be rescued after the treatment with OPC-41 061, OPC-31 260 and OPC-21 268, separately. In conclusion, we think that using pharmacological chaperones in vitro has an importance on developing treatment strategies for these kind of conformational disorders. In the future, we will perform more functional analysis experiments on these mutants after the treatment with OPC-41 061, OPC-31 260 and OPC-21 268, separately. Consequently, all these analysis will make us to understand the precise affect of OPC-41 061, OPC-31 260 and OPC-21 268 in vitro.
- 8 May 2018
- Published by Bioscientifica in Endocrine Abstracts
Tolvaptan; OPC-41 061, Mozavaptan; OPC-31 260, OPC-21 268 as pharmacological chaperones to rescue of mutant AVPR2s
Nefrojenic Diabetes insipidus is one of the typical conformational disorders result from protein misfolding and degredation or aggregation due to the mutations in AVPR2. The patients of nephrogenic Diabetes insipidus have difficulty in concentrate of urine and because of this, they have polyuria, hypoosmolar urine and hypernatremia in variable levels. To make them relieved, many treatment strategies have been studying and using dDAVP nasally is one of these strategies. Another treatment approach on this type of conformational disease is in vitro treatment of mutant AVPR2s with pharmacological chaperones (PCs). PCs are small molecules that bind to misfolded proteins and stabilize them and rescue these mutated proteins from quality control system of Endoplasmic reticulum. In this study, Tolvaptan; OPC-41 061, Mozavaptan; OPC-31 260 and OPC-21 268 were selected as pharmacological chaperones for treatment of previously identified and functionally analyzed mutations (R68W, DR67_G69/G107W and T273M) by our group. As a functional analysis, we performed cell surface ELISA after the treatment of mutant AVPR2s with OPC-41 061, OPC-31 260 and OPC-21 268. Our study was supported by The Scientific and Technological Research Council of Turkey (SBAG Project number 216S304). According to the ELISA results, some mutant AVPR2s could be rescued after the treatment with OPC-41 061, OPC-31 260 and OPC-21 268, separately. In conclusion, we think that using pharmacological chaperones in vitro has an importance on developing treatment strategies for these kind of conformational disorders. In the future, we will perform more functional analysis experiments on these mutants after the treatment with OPC-41 061, OPC-31 260 and OPC-21 268, separately. Consequently, all these analysis will make us to understand the precise affect of OPC-41 061, OPC-31 260 and OPC-21 268 in vitro.
- 3 May 2017
- Published by Bioscientifica in Endocrine Abstracts
Rescue study of trapped AVPR2 mutants with chemicals
Diabetes insipidus (DI) is a disorder that characterized by producing large volume of urine for daily due to the problems at the arginine vasopressin (AVP-NPII), aquaporin 2 (AQP2) and arginine vasopressin receptor 2 (AVPR2) genes. These problems can be inherited or acquired. Among these genes, AVPR2 is a G protein coupled receptor and most of the inherited type of DI are caused by mutations in AVPR2 gene. Mutations can cause improper folding of the receptor protein and this situation causes to retention of the protein in cellular compartments such as endoplasmic reticulum (ER) or Golgi apparatus. For treatment strategies, researchers try to use chemicals to rescue of mutant proteins from the control mechanisms to make them at least functional. In this study, we aimed to do pre-research for the rescuing mutant receptors (R68W, V162A, T273M, R67_G69del/G107W, V88M, R106C, G12E). We performed functional characterization of these mutant receptors in our previous study and they were observed as trapped in the ER or Golgi apparatus. In the present study, COS-7 cells were transfected with mutant and wild type AVPR2s. 48 hours after the transfection, different concentrations of DMSO and glycerol were performed to the cells. 16–18 hours after the treatment of DMSO and glycerol, cell surface ELISA were performed to understand cell surface expression of the mutant proteins when they were treated with different concentrations of DMSO and glycerol. According to the ELISA results, mutant receptors showed different rescue profile compared to the wild type receptor. As a result, we can say that rescuing trapped mutant receptors from ER or Golgi apparatus control mechanisms using with chemicals could be a forward step for the treatment of DI. Receptors that have mutations which cause retention in ER or Golgi apparatus may be functional if they are rescued by chemicals. For further studies, instead of chemicals, pharmacochaperons could be use. We can conclude that, rescue studies of mutated proteins by using chemicals or pharmacochaperons shed light to the treatment strategies of DI. This work was supported by The Scientific and Technological Research Council of Turkey (Project Numbers: 216S304 and 112S513).
- 3 May 2017
- Published by Bioscientifica in Endocrine Abstracts
Rescue study of trapped AVPR2 mutants with chemicals
Diabetes insipidus (DI) is a disorder that characterized by producing large volume of urine for daily due to the problems at the arginine vasopressin (AVP-NPII), aquaporin 2 (AQP2) and arginine vasopressin receptor 2 (AVPR2) genes. These problems can be inherited or acquired. Among these genes, AVPR2 is a G protein coupled receptor and most of the inherited type of DI are caused by mutations in AVPR2 gene. Mutations can cause improper folding of the receptor protein and this situation causes to retention of the protein in cellular compartments such as endoplasmic reticulum (ER) or Golgi apparatus. For treatment strategies, researchers try to use chemicals to rescue of mutant proteins from the control mechanisms to make them at least functional. In this study, we aimed to do pre-research for the rescuing mutant receptors (R68W, V162A, T273M, R67_G69del/G107W, V88M, R106C, G12E). We performed functional characterization of these mutant receptors in our previous study and they were observed as trapped in the ER or Golgi apparatus. In the present study, COS-7 cells were transfected with mutant and wild type AVPR2s. 48 hours after the transfection, different concentrations of DMSO and glycerol were performed to the cells. 16–18 hours after the treatment of DMSO and glycerol, cell surface ELISA were performed to understand cell surface expression of the mutant proteins when they were treated with different concentrations of DMSO and glycerol. According to the ELISA results, mutant receptors showed different rescue profile compared to the wild type receptor. As a result, we can say that rescuing trapped mutant receptors from ER or Golgi apparatus control mechanisms using with chemicals could be a forward step for the treatment of DI. Receptors that have mutations which cause retention in ER or Golgi apparatus may be functional if they are rescued by chemicals. For further studies, instead of chemicals, pharmacochaperons could be use. We can conclude that, rescue studies of mutated proteins by using chemicals or pharmacochaperons shed light to the treatment strategies of DI. This work was supported by The Scientific and Technological Research Council of Turkey (Project Numbers: 216S304 and 112S513).